Ligand Pharmaceuticals
LGND
187 hedge funds and large institutions have $1.73B invested in Ligand Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 63 increasing their positions, 61 reducing their positions, and 28 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
50% more capital invested
Capital invested by funds: $1.15B → $1.73B (+$576M)
32% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 28
4% more funds holding
Funds holding: 180 → 187 (+7)
3% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 61
3% less call options, than puts
Call options by funds: $8.29M | Put options by funds: $8.53M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
+$27.7M |
| 2 |
William Blair & Company
Chicago,
Illinois
|
+$18.1M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$15M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$12.6M |
| 5 |
Bank of New York Mellon
New York
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$36.4M |
| 2 |
RIM
RS Investment Management
San Francisco,
California
|
-$14.9M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$11.2M |
| 4 |
BC
Broadfin Capital
New York
|
-$10.6M |
| 5 |
RCMC
RK Capital Management (Colorado)
Denver,
Colorado
|
-$8.06M |
LGND Hedge Fund Activity: Q1 2015 in Review
187 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2015, worth a combined $1.73B — up 50% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new LGND positions and 28 closed out — a net gain of 9 holders — while 63 added to existing stakes and 61 trimmed.
The largest buyer was Oak Ridge Investments, opening a new position worth an estimated $27.7M. The largest seller was BVF Inc, cutting an estimated $36.4M.
- 187 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2015, up from 180 in Q4 2014.
- Funds reported $1.73B of Ligand Pharmaceuticals stock for Q1 2015, up 50% quarter-over-quarter.
- 37 funds opened new Ligand Pharmaceuticals positions in Q1 2015 and 28 closed out, a net change of +9 holders.
- The largest Ligand Pharmaceuticals buyer in Q1 2015 was Oak Ridge Investments, an estimated $27.7M added.
- The largest Ligand Pharmaceuticals seller in Q1 2015 was BVF Inc, an estimated $36.4M sold.
Based on aggregated 13F filings for Q1 2015.